How India Exports Ipratropium to the World

In the United States, ipratropium bromide has been approved through both New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs). The FDA approved the first NDA for ipratropium bromide inhalation solution (NDA #75-111) on April 22, 1999, submitted by Alpharma U.S. Pharmaceuticals Division. Subsequently, multiple ANDAs have been approved, facilitating the entry of generic versions into the market. Notably, as of February 12, 2026, the FDA has not approved a generic version of Atrovent HFA, a specific formulation of ipratropium bromide.

The substantial export of ipratropium from India to the U.S., amounting to 28.5% of total exports, underscores the importance of compliance with FDA regulations. Indian manufacturers must adhere to stringent FDA requirements, including Good Manufacturing Practices (GMP), to ensure product quality and safety. The presence of 173 active Indian exporters indicates a competitive landscape, necessitating continuous regulatory vigilance to maintain market access.

In the European Union (EU) and the United Kingdom (UK), ipratropium bromide is subject to marketing authorization by the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA), respectively. The EMA has conducted periodic safety update report single assessments (PSUSAs) for ipratropium-containing products, such as the assessment completed on November 27, 2017. (ema.europa.eu) Additionally, the MHRA issued a Class 3 medicines recall for a batch of ipratropium bromide nebuliser solution on October 23, 2025, due to labeling issues. (gov.uk)

Compliance with EU and UK GMP requirements is mandatory for Indian exporters targeting these markets. This includes adherence to guidelines on manufacturing processes, quality control, and pharmacovigilance to ensure product safety and efficacy.

Ipratropium bromide is listed in the WHO Model List of Essential Medicines, highlighting its critical role in treating respiratory conditions. The inclusion in the 6th WHO Model List of Essential Medicines for Children, published in April 2017, further emphasizes its importance. (tdr.who.int) Indian manufacturers exporting ipratropium must ensure compliance with international pharmacopoeia standards, including those of the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to meet global quality expectations.

In India, ipratropium bromide is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing to ensure affordability. Exporting ipratropium requires a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national export regulations.

The primary patents for ipratropium bromide have expired, allowing for generic competition. However, certain formulation and device patents, such as the inhaler device patent (US8474447), remain active until January 2030. This ongoing patent protection may influence market dynamics and the entry of new generic formulations.

In October 2025, the MHRA issued a Class 3 medicines recall for a batch of ipratropium bromide nebuliser solution due to labeling discrepancies, underscoring the importance of stringent quality control measures. (gov.uk)

Additionally, as of February 12, 2026, the FDA has not approved a generic version of Atrovent HFA, indicating ongoing market exclusivity for this formulation.

These developments highlight the necessity for Indian exporters to maintain rigorous compliance with international regulatory standards to ensure continued market access and competitiveness.

Ipratropium, a bronchodilator used in the treatment of respiratory conditions, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) often relies on Key Starting Materials (KSMs) sourced from China. This dependency exposes the supply chain to potential disruptions stemming from geopolitical tensions, trade restrictions, or production issues within China. For instance, a 2025 study by the U.S. Pharmacopeia highlighted that 41% of KSMs used in U.S.-approved medicines are sourced solely from China, underscoring the vulnerability of pharmaceutical supply chains to such concentrated sourcing.

Recent events have further exacerbated these risks. In February 2026, escalating conflicts in the Middle East led to the effective shutdown of the Strait of Hormuz, a critical maritime chokepoint. This disruption has significantly impacted the transportation of raw materials, including those essential for pharmaceutical manufacturing, causing delays and potential shortages in API production.

Our proprietary trade data from 2022 to 2026 reveals a high concentration in the export of Ipratropium from India. The top five exporters account for 95.0% of the total export value, with CIPLA LIMITED alone contributing 84.7% ($48.3 million USD). This significant concentration poses a single-source risk; any operational or regulatory issues affecting CIPLA LIMITED could disrupt the global supply of Ipratropium.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to diversify and strengthen domestic pharmaceutical manufacturing. While this initiative has encouraged investment in API production, its impact on reducing supplier concentration for Ipratropium remains to be fully realized.

The closure of the Strait of Hormuz in February 2026 has had profound implications for global supply chains. Approximately 20% of the world's oil passes through this strait, and its disruption has led to increased shipping costs and delays. These challenges extend to the pharmaceutical sector, affecting the timely delivery of raw materials and finished products.

Additionally, tensions in the Red Sea and the Strait of Hormuz have heightened risks for commercial shipping. The International Maritime Organization has reported increased threats to vessels in these regions, leading to rerouting and further delays. Such geopolitical instability underscores the fragility of supply chains reliant on these critical maritime routes.

• Diversify API and KSM Sourcing: Encourage the development of alternative suppliers for Ipratropium's API and KSMs in regions less susceptible to geopolitical tensions, reducing dependency on China.

• Enhance Supplier Base: Promote the growth of additional manufacturers within India to decrease reliance on a single exporter, thereby mitigating single-source risks.

• Strengthen Domestic Production: Leverage the PLI scheme to bolster domestic API manufacturing capabilities, ensuring a more resilient supply chain.

• Develop Contingency Plans: Establish strategic reserves of critical raw materials and finished products to buffer against supply chain disruptions.

• Monitor Geopolitical Developments: Implement robust monitoring systems to anticipate and respond proactively to geopolitical events that may impact supply chains.

RISK_LEVEL: HIGH